Skip to main content
Fig. 4 | BMC Women's Health

Fig. 4

From: Novel, disposable, self-inserted, vaginal device for the non-surgical management of pelvic organ prolapse: efficacy, safety, and quality of life

Fig. 4

Comparison of objective efficacy (POP-Q staging) before and while using the ProVate Device. Before using ProVate, 70.21% of users had POP-Q stage 3 prolapse, whereas 29.79% had stage 2 prolapse. While using ProVate, 100% of subjects had a substantial reduction of prolapse to POP-Q stage 0/1. (POP-Q = Pelvic Organ Prolapse Quantification)

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us